Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 16 points (-0.1%) at 18,296 as of Wednesday, May 20, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,497 issues advancing vs. 1,463 declining with 190 unchanged. The Drugs industry currently sits up 0.6% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Sarepta Therapeutics ( SRPT), up 56.5%, ISIS Pharmaceuticals ( ISIS), up 3.1%, Endo International ( ENDP), up 3.0%, Opko Health ( OPK), up 3.0% and United Therapeutics ( UTHR), up 2.8%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $6.19 (1.2%) to $510.34 on average volume. Thus far, 445,987 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 835,700 shares. The stock has ranged in price between $503.42-$514.50 after having opened the day at $507.50 as compared to the previous trading day's close of $504.15. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $50.3 billion and is part of the health care sector. Shares are up 22.9% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Regeneron Pharmaceuticals Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.